文献速递神经肿瘤

范可尼贫血通路失活增强胶质瘤对洛莫司汀敏感性

Fanconi anemia pathway disruption drives lomustine sensitivity in glioma.
PubMed 文献 · Neuro Oncol · 2026-10-10

该研究用CRISPR-Cas9全基因组敲除筛选在实验性胶质瘤中寻找洛莫司汀(CCNU)应答的调控因子,并通过免疫 competent 胶质瘤小鼠模型验证。范可尼贫血(FA)通路多个成员反复出现为CCNU的合成致死交互因子,体内敲低Fancm加速肿瘤发生并显著提高CCNU敏感性,FA通路抑制在体外、离体和体内模型中均增强CCNU疗效。

要点

  • FA通路成员是CCNU应答的关键合成致死交互因子
  • 体内敲低Fancm加速肿瘤发生并显著增加CCNU敏感性
  • FA通路抑制在体外、离体与体内模型中均增强CCNU疗效

核心结论

  • FA通路组分是CCNU应答的关键合成致死交互因子,揭示了胶质母细胞瘤中可治疗利用的脆弱点。

研究设计与样本

  • 采用CRISPR-Cas9全基因组功能敲除筛选鉴定并验证实验性胶质瘤中CCNU应答的调控因子。
  • 建立免疫 competent 胶质瘤小鼠模型,利用RCAS/tv-a体细胞基因递送系统在体内功能 interrogate FA基因与CCNU的合成致死交互。

主要发现

  • 多个FA通路成员反复出现为CCNU治疗的强效合成致死交互因子。
  • 体内敲低Fancm加速肿瘤发生并显著增加CCNU敏感性。
  • FA通路抑制在体外、离体和体内模型中均增强CCNU疗效。

临床怎么用

  • 短期内可能为洛莫司汀治疗的患者分层策略提供信息,长期可支持新型联合治疗开发。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Therapeutic options for progressive glioblastoma remain limited, with chlorethyl-cyclohexyl-nitrosourea (CCNU, lomustine) among the approved treatments. Beyond MGMT gene promoter methylation, molecular determinants of CCNU sensitivity or resistance are ill- defined. METHODS: We employed genome-wide functional knockout screening using the CRISPR-Cas9 technology to identify and subsequently validate modulators of response to CCNU in experimental glioma. We established an immunocompetent glioma mouse model to enable functional interrogation of Fanconi anemia pathway (FA) genes in tumor growth and synthetic lethal interactions in vivo using the RCAS/tv-a somatic gene delivery system. RESULTS: Multiple FA pathway members recurrently emerged as potent synthetic lethal interactors of CCNU treatment. In vivo knockdown of Fancm accelerated tumor onset and significantly increased CCNU sensitivity. Consistently, FA pathway inhibition enhanced CCNU efficacy across in vitro, ex vivo and in vivo models. CONCLUSION: Together, these findings identify FA pathway components as key synthetic lethal interactors of CCNU response and reveal a therapeutically actionable vulnerability in glioblastoma. Treatment options for glioblastoma are very limited. This study examined molecular modulators of treatment sensitivity regarding the approved drug lomustine. Using a functional genomic screening approach and different cell-based and in vivo models, this study discoverd that glioblastomas with reduced activity in a group of genes responsible for repairing damaged DNA are more sensitive to lomustine. Lowering the activity of one key gene, called FancM, strongly improved the effect of lomustine. These results might inform strategies to patient stratification for lomustine treatment in the short run while enabling novel combination therapies in the long term.

来源:Neuro Oncol,查看原文。版权归原作者所有。

引用

  1. Becker H, Walter B, Haeusser LA, et al. Fanconi anemia pathway disruption drives lomustine sensitivity in glioma. Neuro Oncol. 2026. PMID: 42858234. doi:10.1093/neuonc/noag254

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。